Measuring disease modification in MPN clinical trials

The MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about measuring disease modification in MPN clinical trials. 

Barbui begins by discussing established response criteria and the multi-parameter context of disease modification in myeloproliferative neoplasms, summarizing surrogate and non-surrogate markers. He highlights the complex situation in myelofibrosis compared with polycythemia vera and essential thrombocytosis in this regard.

Kiladjian then raises the challenges around these parameters and opens a discussion on whether artificial intelligence would be useful for a more objective and standardized response assessment in clinical trials.

They also touch upon measuring the molecular response inflammation in disease modification.